Payment overview · 2025
General Payments
$847.50
39 reported records · 15 companies
Healthcare provider profile · identity verified
Anton Koopman, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, IN · NPI 1538182035
Verified facts
What the public records show
CMS Open Payments records show Anton Koopman, MD received $847.50 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $321.93 | 38.0% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.15 | 10.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.49 | 10.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.57 | 8.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.64 | 7.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.49 | 4.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.37 | 4.1% | 2 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $31.35 | 3.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.13 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.43 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.45 | 1.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.64 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.77 | 1.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.98 | 1.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $9.11 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.50 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $241.40 | 3 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $213.16 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $75.57 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.37 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.70 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.37 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $9.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 319 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 290 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 252 | 34 |
| Losartan Potassium | Losartan Potassium | 230 | 65 |
| Celecoxib | Celecoxib | 213 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 47 |
| Furosemide | Furosemide | 178 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 173 | 48 |
| Trazodone Hcl | Trazodone Hcl | 152 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 40 |
| Lorazepam | Lorazepam | 134 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 31 |
| Clonazepam | Clonazepam | 128 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 35 |
| Alprazolam | Alprazolam | 120 | 20 |
| Tramadol Hcl | Tramadol Hcl | 118 | 26 |
| Allopurinol | Allopurinol | 117 | 31 |
| Azithromycin | Azithromycin | 115 | 76 |
| Metformin Hcl Er | Metformin Hcl | 112 | 33 |
| Lisinopril | Lisinopril | 104 | 34 |
| Prednisone | Prednisone | 99 | 61 |
| Gabapentin | Gabapentin | 97 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 23 |
| Montelukast Sodium | Montelukast Sodium | 92 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 30 |
| Cefuroxime | Cefuroxime Axetil | 85 | 61 |
| Meloxicam | Meloxicam | 83 | 25 |
| Simvastatin | Simvastatin | 83 | 23 |
| Mounjaro | Tirzepatide | 82 | 17 |
| Glimepiride | Glimepiride | 80 | 23 |
| Omeprazole | Omeprazole | 77 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 16 |
| Potassium Chloride | Potassium Chloride | 60 | 18 |
| Ondansetron Odt | Ondansetron | 59 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Alendronate Sodium | Alendronate Sodium | 57 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 19 |
| Pregabalin | Pregabalin | 55 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 14 |
| Donepezil Hcl | Donepezil Hcl | 53 | 12 |
| Temazepam | Temazepam | 53 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Cephalexin | Cephalexin | 49 | 29 |
| Carvedilol | Carvedilol | 48 | 16 |
| Diazepam | Diazepam | 45 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 43 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | 18 |
| Levofloxacin | Levofloxacin | 37 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Mometasone Furoate | Mometasone Furoate | 31 | 17 |
| Famotidine | Famotidine | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Metformin Hcl | Metformin Hcl | 30 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 27 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Baclofen | Baclofen | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 16 |
| Mupirocin | Mupirocin | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Torsemide | Torsemide | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Acitretin | Acitretin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $847.50 · 39 records | AstraZeneca Pharmaceuticals LP | Auvelity, Azstarys, BEVESPI AEROSPHERE, CYCLOSET, Cologuard Collection Kit, ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error